Japanese encephalitis is a disease caused by the mosquito-borne Japanese encephalitis virus (JEV). Japanese Encephalitis Vaccine acts by inducing antibodies that neutralize live JEV.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J07BA03 | J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BA Encephalitis vaccines | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| IXIARO Japanese Encephalitis Vaccine | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Japanese encephalitis, live attenuated is an active ingredient of these brands:
United States (US)Austria (AT)Canada (CA)Croatia (HR)Estonia (EE)Finland (FI)France (FR)Ireland (IE)Israel (IL)Italy (IT)Lithuania (LT)Netherlands (NL)New Zealand (NZ)
Poland (PL)Spain (ES)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
